ALSO NOTED: Shasun sets up NJ plant; Barrier gets a new CEO; Pharming gains grant; and much more...

> India's Shasun Chemicals has set up a processing unit for active pharmaceutical ingredients in New Jersey to supply U.S. customers. Report

> Chutes & Ladders: The chief operating officer of Barrier Therapeutics, Alfred Altomari, has been named CEO, succeeding Geert Cauwenbergh. Report

> Pharming has received a grant of €905,000 to research premature aging. Report

> German regulators have cleared Celgene's takeover of Pharmion. Release

> More than 100 allergic reactions, including one possible death, prompted Baxter International to recall its anti-clotting drug heparin. Report

> It's official: Merck's off-patent statin drug Mevacor can't go over-the-counter. Report

> The FDA has plans to review the controversial Enhance study. Report

> Is pharma addicted to producing blockbuster drugs? Report

And Finally… Opening up gorilla and chimpanzee reserves to tourists is raising fears that the animals will become infected by virulent human viruses. Release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.